We will have limited operations from 15:00 Tuesday 24 December 2024 (AEDT) until Thursday 2 January 2025. Find out how to contact us during the holiday period.
CAMZYOS (Bristol-Myers Squibb Australia Pty Ltd)
Product name
CAMZYOS
Date registered
Evaluation commenced
Decision date
Approval time
195 (255 working days)
Active ingredients
mavacamten
Registration type
NCE/NBE
Indication
CAMZYOS is indicated for the treatment of adults with symptomatic NYHA class II-III obstructive hypertrophic cardiomyopathy.